Category Archives: Uncategorized

Microbiological Data

Precision in microbiological data is critical. Nitto Avecia Pharma Services offers extensive testing services via our highly experienced microbiology team. Avecia offers a broad range of compliant, high quality microbiological services. Tests are performed according to official compendial, or industry recognized, and client-provided methodologies. Learn more about how Avecia can help.

Nitto Denko Avecia, Inc. Acquires the Businesses of Irvine Pharmaceutical Services & Avrio Biopharmaceuticals

MILFORD, MA – Nitto Denko Avecia, Inc. (Avecia), today announced it has entered into a definitive agreement to acquire the assets of Irvine Pharmaceutical Services (Irvine) and Avrio Biopharmaceuticals (Avrio), both located in Irvine, CA. Irvine is a leading analytical development services provider and Avrio is a premier cGMP parenteral contract manufacturing organization. Avecia will … Continue reading Nitto Denko Avecia, Inc. Acquires the Businesses of Irvine Pharmaceutical Services & Avrio Biopharmaceuticals

Nitto Avecia Announces Multiple Oligonucleotide Expansions

MILFORD, MA – Nitto Avecia Inc. (Avecia) today released its progress in expanding the company’s analytical development and oligonucleotide manufacturing capacities. The announcement signals the continuation of Avecia’s robust growth strategy to significantly increase its oligonucleotide drug substance manufacturing capacity in Milford, MA along with the addition of drug product capacity in Irvine, CA and … Continue reading Nitto Avecia Announces Multiple Oligonucleotide Expansions

AAPS National Biotechnology Conference

We will be attending the AAPS National Biotechnology Conference in San Diego from May 1st to May 3rd. This year’s main topics for the conference will be: Bioanalysis & Biomarkers, Biosimilars, Emerging Topics, Formulation Development, Drug Delivery & Manufacturing, and Novel Therapeutic Constructs & Modalities, including Immunotherapies. We would love to see you there. Come … Continue reading AAPS National Biotechnology Conference

Nitto Denko Avecia Announces Opening of Manufacturing Expansion

Nitto Denko Avecia Inc. (Avecia) has announced the opening of its new oligonucleotide API (active pharmaceutical ingredients) manufacturing facility in Milford, MA. The opening will commence with a ribbon cutting ceremony in August 2017 onsite at the Milford, MA facility. The ceremony will open with remarks from: Hideo Takasaki, CEO, Nitto Denko CorporationJay Ash, MA … Continue reading Nitto Denko Avecia Announces Opening of Manufacturing Expansion

Nitto Avecia Completes Multiple Successful Oligonucleotide Manufacturing Synthesis Runs at 1.6 Mol Scale

MILFORD, MA – Nitto Avecia, Inc. (Avecia) announced today the successful completion of the first synthesis runs at the 1.6 Mol scale which is believed to be the largest synthesis scale ever executed for oligonucleotide API (active pharmaceutical ingredients) at its new oligonucleotide manufacturing facility in Milford, MA. This exciting news comes only months after … Continue reading Nitto Avecia Completes Multiple Successful Oligonucleotide Manufacturing Synthesis Runs at 1.6 Mol Scale

Nitto Avecia Pharma Services Appoints Raymond Kaczmarek as President

NITTO AVECIA PHARMA SERVICES APPOINTS RAYMOND KACZMAREK AS PRESIDENT IRVINE, CA – Nitto Avecia Pharma Services, Inc. (Avecia Pharma), a leading CGMP contract development and manufacturing organization (CDMO), announced today that it has appointed Raymond Kaczmarek to the position of President. Mr. Kaczmarek will have full P&L responsibility for the entire organization. Detlef Rethage, President … Continue reading Nitto Avecia Pharma Services Appoints Raymond Kaczmarek as President

XTALKS PRESS RELEASE FOR Nitto Avecia Pharma (April 17/18 Webinar)

HEADLINE Cell-Based Assays in a CGMP Environment: Approaches for Clinical and Commercial Stability Studies, New Webinar Hosted by Xtalks. SUB-HEADLINE Presentation to highlight the approaches used in developing consistent cell-based potency assays meeting regulatory expectations (USP <1032> and <1033>) and are suitable for CGMP stability testing. SUMMARY Potency of biotherapeutics, often determined by cell-based assays, … Continue reading XTALKS PRESS RELEASE FOR Nitto Avecia Pharma (April 17/18 Webinar)